Compare · DRIO vs DXCM
DRIO vs DXCM
Side-by-side comparison of DarioHealth Corp. (DRIO) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRIO and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $31.50B, about 589.8x DRIO ($53.4M).
- Over the past year, DRIO is down 62.6% and DXCM is up 29.7% - DXCM leads by 92.3 points.
- DRIO has been more active in the news (10 items in the past 4 weeks vs 6 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 5 for DRIO).
- Company
- DarioHealth Corp.
- DexCom Inc.
- Price
- $5.00-5.12%
- $86.03-1.95%
- Market cap
- $53.4M
- $31.50B
- 1M return
- -27.64%
- -2.12%
- 1Y return
- -62.63%
- +29.71%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 10
- 6
- Recent ratings
- 5
- 25
DarioHealth Corp.
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is based in New York, New York.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DRIO
- DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs
- Director Shaked Yoav converted options into 772 shares and was granted 54,000 shares, increasing direct ownership by 167% to 87,582 units (SEC Form 4)
- Director Mcgrath Dennis M was granted 61,000 shares, increasing direct ownership by 220% to 88,737 units (SEC Form 4)
- Director Palumbo John R was granted 62,000 shares, increasing direct ownership by 1,378% to 66,500 units (SEC Form 4)
- Director Stern Adam K converted options into 20,195 shares and was granted 28,000 shares, increasing direct ownership by 94% to 57,717 units (SEC Form 4)
- Director Matheis Dennis was granted 44,000 shares, increasing direct ownership by 102% to 87,026 units (SEC Form 4)
- Chief Financial Officer Franco-Yehuda Chen was granted 95,000 shares, increasing direct ownership by 317% to 125,000 units (SEC Form 4)
- Director Karah Hila was granted 28,000 shares, increasing direct ownership by 90% to 58,965 units (SEC Form 4)
- Chief Executive Officer Raphael Erez converted options into 579 shares and was granted 297,000 shares, increasing direct ownership by 190% to 454,432 units (SEC Form 4)
- New insider Sherman Lara Ann claimed ownership of 120,000 shares (SEC Form 3)
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer